

## Referenzen

1. Galieva LR, Mukhamedshina YO, Arkhipova SS, Rizvanov AA. Human Umbilical Cord Blood Cell Transplantation in Neuroregenerative Strategies. *Front Pharmacol*. 2017;8:628. doi:10.3389/fphar.2017.00628.
2. Mayani H, Wagner JE, Broxmeyer HE. Cord blood research, banking, and transplantation: achievements, challenges, and perspectives. *Bone Marrow Transplant*. 2019. doi:10.1038/s41409-019-0546-9.
3. Broxmeyer HE. *StemBook: Cord blood hematopoietic stem cell transplantation\**. Cambridge (MA); 2008. <https://www.ncbi.nlm.nih.gov/books/NBK44751/>. Accessed April 29, 2019.
4. Bundesärztekammer. Richtlinie zur Herstellung und Anwendung von hämatopoetischen Stammzellzubereitungen – Erste Fortschreibung. *Dtsch Arztebl International*. 2019;116(11):A-546. doi:10.3238/arztebl.2019.rl\_haematop\_sz02.
5. The American Cancer Society medical and editorial content team. Types of Stem Cell and Bone Marrow Transplants. <https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/stem-cell-transplant/types-of-transplants.html>. Updated 03.2020. Accessed August 11, 2022.
6. Bastida JM, Cabrero M, Lopez-Godino O, et al. Influence of donor age in allogeneic stem cell transplant outcome in acute myeloid leukemia and myelodysplastic syndrome. *Leuk Res*. 2015;39(8):828-834. doi:10.1016/j.leukres.2015.05.003.
7. Rezvani AR, Storer BE, Guthrie KA, et al. Impact of donor age on outcome after allogeneic hematopoietic cell transplantation. *Biol Blood Marrow Transplant*. 2015;21(1):105-112. doi:10.1016/j.bbmt.2014.09.021.
8. Galamidi-Cohen E, Joyce A, Simantov R. Impact of Donor Age on Outcomes in Hematopoietic Stem Cell Transplantation. *Stem Cells Transl Med*. 2020;9(S1). doi:10.1002/sctm.12812.
9. Mariotti J, Raiola AM, Evangelista A, et al. Impact of donor age and kinship on clinical outcomes after T-cell-replete haploidentical transplantation with PT-Cy. *Blood Adv*. 2020;4(16):3900-3912. doi:10.1182/bloodadvances.2020001620.
10. Gluckman Eliane, Broxmeyer Hal E., Auerbach Arleen D., et al. Hematopoietic Reconstitution in a Patient with Fanconi's Anemia by Means of Umbilical-Cord Blood from an HLA-Identical Sibling // Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. *N Engl J Med*. 1989;321(17):1174-1178. doi:10.1056/NEJM198910263211707.
11. Dessels C, Alessandrini M, Pepper MS. Factors Influencing the Umbilical Cord Blood Stem Cell Industry: An Evolving Treatment Landscape. *Stem Cells Transl Med*. 2018;7(9):643-650. doi:10.1002/sctm.17-0244.
12. ClinicalTrials.gov. NCT03441958: A Phase I-II Open-label Study of Non-myeloablative-allogeneic Transplant of ECT-001 (UM171/ Fed-batch Culture System) Expanded Cord Blood in Patients With High-risk Multiple Myeloma. <https://clinicaltrials.gov/ct2/show/NCT03441958>. Accessed September 10, 2024.
13. ClinicalTrials.gov. NCT01451502: Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units. <https://clinicaltrials.gov/ct2/show/NCT01451502>. Accessed September 10, 2024.
14. ClinicalTrials.gov. NCT01861093: A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients. <https://clinicaltrials.gov/ct2/show/NCT01861093>. Accessed September 10, 2024.
15. ClinicalTrials.gov. NCT02730299: A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs.

- Unmanipulated UCB for Patients With Hematological Malignancies. [Already published].  
<https://clinicaltrials.gov/ct2/show/NCT02730299>. Accessed September 10, 2024.
16. ClinicalTrials.gov. NCT01962636: Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for the Treatment of Hematological Diseases.  
<https://clinicaltrials.gov/ct2/show/NCT01962636>. Accessed September 10, 2024.
  17. ClinicalTrials.gov. NCT00719888: Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease.  
<https://clinicaltrials.gov/ct2/show/NCT00719888?recrs=abdf&cond=leukemia%2C+lymphoma&intr=umbilical+cord+blood&draw=2&rank=10>. Accessed September 10, 2024.
  18. ClinicalTrials.gov. NCT05669079: Decitabine and Umbilical Cord Blood for Poor Graft Function Post Allo-HSCT. [Phase 3, Taiwan]. <https://www.clinicaltrials.gov/study/NCT05669079>. Updated August 3, 2023. Accessed September 27, 2024.
  19. ClinicalTrials.gov. NCT01810588: Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation. [Phase 2, USA].  
<https://www.clinicaltrials.gov/study/NCT01810588>. Updated August 3, 2023. Accessed September 27, 2024.
  20. ClinicalTrials.gov. NCT03173937: Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome. [Phase 1/2, USA]. <https://www.clinicaltrials.gov/study/NCT03173937>. Updated August 3, 2023. Accessed September 27, 2024.
  21. ClinicalTrials.gov. NCT03739502: A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant (HBO-UBC). [Phase 2, USA].  
<https://www.clinicaltrials.gov/study/NCT03739502>. Updated August 3, 2023. Accessed September 27, 2024.
  22. ClinicalTrials.gov. NCT04644016: Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders. [Phase 2, USA].  
<https://www.clinicaltrials.gov/study/NCT04644016>. Updated August 3, 2023. Accessed September 27, 2024.
  23. ClinicalTrials.gov. NCT04687657: Umbilical Cord Blood Transfusion in Consolidation Therapy of Elderly Patients With Acute Myeloid Leukemia. [Phase 1, China, Unknown Status].  
<https://www.clinicaltrials.gov/study/NCT04687657>. Updated August 3, 2023. Accessed September 27, 2024.
  24. ClinicalTrials.gov. NCT04990323: US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies. [Phase 1/2, USA].  
<https://www.clinicaltrials.gov/study/NCT04990323?intr=Cord%20blood&aggFilters=phase:0%201,status:not%20rec%20act&page=2&rank=16>. Updated August 3, 2023. Accessed September 27, 2024.
  25. ClinicalTrials.gov. NCT05577611: An Open, Single Center, Randomized Controlled Clinical Study of UCB (Cord Blood) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML). [Phase 1, China]. <https://www.clinicaltrials.gov/study/NCT05577611>. Updated August 3, 2023. Accessed September 27, 2024.
  26. ClinicalTrials.gov. NCT05584761: Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML. [Phase 1/2, China].  
<https://www.clinicaltrials.gov/study/NCT05584761=2>. Updated August 3, 2023. Accessed September 27, 2024.
  27. ClinicalTrials.gov. NCT05667155: Clinical Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma. [Phase 1, China].

- <https://www.clinicaltrials.gov/study/NCT05667155>. Updated August 3, 2023. Accessed September 27, 2024.
28. ClinicalTrials.gov. NCT05794425: Clinical Study of UCB Combined With UC-MSCs in the Treatment of Bone Marrow Failure Disorders. [Phase 1/2, China].  
<https://www.clinicaltrials.gov/study/NCT05794425>. Updated August 3, 2023. Accessed September 27, 2024.
  29. ClinicalTrials.gov. NCT05884333: Cord Blood Transplant in Adults With Blood Cancers. [Phase 2, USA]. <https://www.clinicaltrials.gov/study/NCT05884333>. Updated August 3, 2023. Accessed September 27, 2024.
  30. ClinicalTrials.gov. NCT00357565: Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia. [Phase 2, USA]. <https://www.clinicaltrials.gov/study/NCT00357565>. Updated August 3, 2023. Accessed September 27, 2024.
  31. ClinicalTrials.gov. NCT02727803: Personalized NK Cell Therapy in Cord Blood Transplantation. <https://clinicaltrials.gov/ct2/show/NCT02727803>. Accessed September 27, 2024.
  32. ClinicalTrials.gov. NCT03420963: Ex-Vivo Expanded Allogeneic NK Cells for the Treatment of Solid Tumors of Pediatric Origin in Children and Young Adults.  
<https://clinicaltrials.gov/ct2/show/NCT03420963>. Accessed September 27, 2024.
  33. ClinicalTrials.gov. NCT04796675: Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies. [Unknown Status].  
<https://clinicaltrials.gov/ct2/show/NCT04796675?recrs=abdf&cond=leukemia%2C+lymphoma&intr=umbilical+cord+blood&draw=3&rank=7>. Accessed September 27, 2024.
  34. ClinicalTrials.gov. NCT05092451: Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignancies.  
<https://clinicaltrials.gov/ct2/show/NCT05092451?recrs=abdf&cond=leukemia%2C+lymphoma&intr=umbilical+cord+blood&draw=3&rank=11>. Accessed September 27, 2024.
  35. ClinicalTrials.gov. NCT03594981: Adoptive Cord Blood Immunotherapy for EBV, CMV, BKV and Adenovirus Reactivation/Infection or Prophylaxis. [Phase 1/2, USA].  
<https://www.clinicaltrials.gov/study/NCT03594981>. Updated August 3, 2023. Accessed September 27, 2024.
  36. ClinicalTrials.gov. NCT04347616: Natural Killer-cell Therapy for Acute Myeloid Leukemia (NK4AML). [Phase 1/2, Netherlands].  
<https://www.clinicaltrials.gov/study/NCT04347616?intr=Cord%20blood&aggFilters=phase:0%201,status:not%20rec&page=5&rank=49>. Updated August 3, 2023. Accessed September 27, 2024.
  37. ClinicalTrials.gov. NCT04707300: Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies (HTLP-ONCO) (HTLP-ONCO). [Phase 1/2, Frankreich]. <https://www.clinicaltrials.gov/study/NCT04707300>. Updated August 3, 2023. Accessed September 27, 2024.
  38. ClinicalTrials.gov. NCT05240690: Umbilical Cord Blood Derived MAK Immune Cells Combined With Standard Second-Line Treatments for Hepatobiliary and Pancreatic Malignancies. [Phase 1, China]. <https://www.clinicaltrials.gov/study/NCT05240690>. Updated August 3, 2023. Accessed September 27, 2024.
  39. ClinicalTrials.gov. NCT05334329: Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors. [Phase 1, USA].  
<https://www.clinicaltrials.gov/study/NCT05334329>. Updated August 3, 2023. Accessed September 27, 2024.

40. ClinicalTrials.gov. NCT05472558: Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL. [Phase 1, China].  
<https://www.clinicaltrials.gov/study/NCT05472558>. Updated August 3, 2023. Accessed September 27, 2024.
41. ClinicalTrials.gov. NCT04991870: Engineered NK Cells Containing Deleted TGF-BetaR2 and NR3C1 for the Treatment of Recurrent Glioblastoma. [Phase 1, USA].  
<https://www.clinicaltrials.gov/study/NCT04991870>. Updated August 3, 2023. Accessed September 27, 2024.
42. ClinicalTrials.gov. NCT05110742: Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignancies. [Phase 1/2, USA].  
<https://www.clinicaltrials.gov/study/NCT05110742?intr=Cord%20blood&aggFilters=phase:0%201,status:not%20rec&page=5&rank=44>. Updated August 3, 2023. Accessed September 27, 2024.
43. ClinicalTrials.gov. NCT05703854: Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma. [Phase 1/2, USA].  
<https://www.clinicaltrials.gov/study/NCT05703854?intr=Cord%20blood&aggFilters=phase:0%201,status:not%20rec&page=5&rank=50>. Updated August 3, 2023. Accessed September 27, 2024.
44. ClinicalTrials.gov. NCT05842707: Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma. [Phase 1/2, China].  
<https://www.clinicaltrials.gov/study/NCT05842707?intr=Cord%20blood&aggFilters=phase:0%201,status:not%20rec&page=4&rank=35>. Updated August 3, 2023. Accessed September 27, 2024.
45. ClinicalTrials.gov. NCT04768816: Clinical Effect and Safety of Autologous Umbilical Cord Blood Transfusion in the Treatment of Autism Spectrum Disorder. [Phase 1, China].  
<https://www.clinicaltrials.gov/study/NCT04768816>. Updated August 3, 2023. Accessed September 27, 2024.
46. ClinicalTrials.gov. NCT04243382: Treatment of Children With Autistic Spectrum Disorder With Autologous Umbilical Cord Blood, a Pilot Study. [Phase 2, Israel].  
<https://www.clinicaltrials.gov/study/NCT04243382>. Updated August 3, 2023. Accessed September 27, 2024.
47. ClinicalTrials.gov. NCT02881970: Neonatal Hypoxic Ischemic Encephalopathy : Safety and Feasibility Study of a Curative Treatment With Autologous Cord Blood Stem Cells (NEOSTEM).  
<https://clinicaltrials.gov/ct2/show/NCT02881970>. Accessed September 27, 2024.
48. ClinicalTrials.gov. NCT04243408: Treatment of Children With Cerebral Palsy With Autologous Umbilical Cord Blood, a Pilot Study.  
<https://clinicaltrials.gov/ct2/show/NCT04243408?recrs=abdf&cond=cerebral+palsy&intr=cord+blood&draw=2&rank=1>. Accessed September 27, 2024.
49. ClinicalTrials.gov. NCT03327467: Expanded Access Protocol: Umbilical Cord Blood Infusions for Children With Brain Injuries. [Expanded Access; USA].  
<https://clinicaltrials.gov/study/NCT03327467?term=NCT03327467&rank=1>. Updated August 7, 2023. Accessed September 27, 2024.
50. ClinicalTrials.gov. NCT03779711: Phase IIb Study of Intramyocardial Injection of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Stage II Surgical Repair of Right Ventricular Dependent Variants of Hypoplastic Left Heart Syndrome (AutoCell-S2).  
<https://clinicaltrials.gov/ct2/show/NCT03779711>. Accessed June 21, 2019.
51. ClinicalTrials.gov. NCT04907526: Intramyocardial Injection of Autologous UCB-MNC During Fontan Surgery for SRV Dependent CHD.  
<https://clinicaltrials.gov/ct2/show/NCT04907526?recrs=abdf&cond=heart&intr=cord+blood&draw=2&rank=3>. Accessed September 27, 2024.

52. ClinicalTrials.gov. NCT01632475: Long Term Follow-Up Study of the Safety and Exploratory Efficacy of Pneumostem® in Premature Infants With Bronchopulmonary Dysplasia. <https://clinicaltrials.gov/ct2/show/NCT01632475>. Accessed September 27, 2024.
53. ClinicalTrials.gov. NCT04003857: Follow-up Study of Safety and Efficacy in Subjects Who Completed PNEUMOSTEM® Phase II (MP-CR-012) Clinical Trial. <https://clinicaltrials.gov/ct2/show/NCT04003857?recrs=abdf&cond=lung&intr=cord+blood&draw=2&rank=8>. Accessed September 27, 2024.
54. ClinicalTrials.gov. NCT03835312: Sequential Transplantation of Umbilical Cord Blood Stem Cells and Islet Cells in Children and Adolescents With Monogenic Immunodeficiency Type 1 Diabetes Mellitus. <https://clinicaltrials.gov/ct2/show/NCT03835312>. Accessed September 27, 2024.
55. ClinicalTrials.gov. NCT04943289: Intrathecal Administration of DUOC-01 in Adults With Primary Progressive Multiple Sclerosis (DUOC for MS). <https://clinicaltrials.gov/ct2/show/NCT04943289?recrs=abdf&cond=autoimmune&intr=cord+blood&draw=2&rank=5>. Accessed September 27, 2024.
56. ClinicalTrials.gov. NCT04689425: Umbilical Cord Blood Mononuclear Cell Gel in the Treatment of Refractory Diabetic Foot Ulcer (DFU-MNC). [Phase 3, China]. <https://www.clinicaltrials.gov/study/NCT04689425>. Updated August 3, 2023. Accessed September 27, 2024.
57. ClinicalTrials.gov. NCT02254863: Augmentation of Umbilical Cord Blood Transplantation for Inherited Metabolic Diseases With Intrathecal Administration of Human Umbilical Cord Blood-Derived Oligodendrocyte-Like Cells. <https://clinicaltrials.gov/ct2/show/NCT02254863>. Accessed September 27, 2024.
58. ClinicalTrials.gov. NCT03016806: Umbilical Cord Blood Transplantation From Unrelated Donors. <https://clinicaltrials.gov/ct2/show/NCT03016806>. Accessed September 27, 2024.
59. ClinicalTrials.gov. NCT01962415: Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT (HSCT+RIC). <https://clinicaltrials.gov/ct2/show/NCT01962415?recrs=abdf&cond=Metabolic+Disease&intr=cord+blood&draw=2&rank=7>. Accessed September 27, 2024.
60. ClinicalTrials.gov. NCT04565665: Cord Blood-Derived Mesenchymal Stem Cells for the Treatment of COVID-19 Related Acute Respiratory Distress Syndrome. [Phase 1/2, USA]. <https://www.clinicaltrials.gov/study/NCT04565665>. Updated August 3, 2023. Accessed September 27, 2024.
61. ClinicalTrials.gov. NCT05682560: Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients With Post-COVID Syndrome. [Phase 2, USA]. <https://www.clinicaltrials.gov/study/NCT05682560>. Updated August 3, 2023. Accessed September 27, 2024.
62. ClinicalTrials.gov. NCT05695521: Regulatory T Cells for Amyotrophic Lateral Sclerosis (REGALS). [Phase 1, USA]. <https://www.clinicaltrials.gov/study/NCT05695521>. Updated August 3, 2023. Accessed September 27, 2024.
63. ClinicalTrials.gov. NCT03979742: Umbilical Cord Blood Cell (MC001) Transplant Into Injured Spinal Cord Followed by the Locomotor Training. [Phase 2, Taiwan]. <https://www.clinicaltrials.gov/study/NCT03979742>. Updated August 3, 2023. Accessed August 7, 2023.
64. ClinicalTrials.gov. NCT05095597: Umbilical Cord Plasma for Treating Endometrial Pathologies (Thin Endometrium / Asherman's Syndrome/ Endometria Atrophy) (hSCU-PRP). [Phase 2, Spanien]. <https://www.clinicaltrials.gov/study/NCT05095597>. Updated August 3, 2023. Accessed September 10, 2024.
65. ClinicalTrials.gov. NCT05303727: Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma. [Phase 2, China]. <https://www.clinicaltrials.gov/study/NCT05303727>. Updated August 3, 2023. Accessed September 10, 2024.

66. ClinicalTrials.gov. NCT05345418: Umbilical Cord-Derived Mesenchymal Stem Cell (VCELL 1) for Male Patients With Sexual Deficiency. [Phase 1/2, Vietnam].  
<https://clinicaltrials.gov/study/NCT05345418>. Updated July 10, 2023. Accessed July 31, 2024.
67. ClinicalTrials.gov. NCT05495711: hUC Mesenchymal Stem Cells (19#iSCLife®-UT) Therapy for Patients With Thin Endometrial Infertility. [Phase 1, China].  
<https://www.clinicaltrials.gov/study/NCT05495711>. Updated July 10, 2023. Accessed July 31, 2024.
68. ClinicalTrials.gov. NCT03826433: hUC Mesenchymal Stem Cells (19#iSCLife®-LC) in the Treatment of Decompensated Hepatitis b Cirrhosishepatitis b Cirrhosis. [Phase 1, China].  
<https://www.clinicaltrials.gov/study/NCT03826433>. Updated July 10, 2023. Accessed July 31, 2024.
69. ClinicalTrials.gov. NCT05512988: Study of Human Umbilical Cord Mesenchymal Stem Cell in Patients With Cirrhosis Due to Hepatitis B (Compensation Stage). [Leber-Erkr., Phase 1/2, China].  
<https://www.clinicaltrials.gov/study/NCT05507762?intr=UC-MSCs&aggFilters=phase:1%200,status:rec&rank=3>. Updated July 10, 2023. Accessed August 3, 2023.
70. ClinicalTrials.gov. NCT04125329: Umbilical Cord Mesenchymal Stem Cells Therapy for Diabetic Nephropathy. [Phase 1, CHina]. <https://www.clinicaltrials.gov/study/NCT04125329?intr=UC-MSCs&aggFilters=phase:1%200,status:rec&page=3&rank=27>. Updated July 10, 2023. Accessed July 31, 2024.
71. ClinicalTrials.gov. NCT05512988: Human Umbilical Cord Mesenchymal Stem Cell(UC- MSC)Delayed Renal Chronic Kidney Disease(CKD3、 4 ). [Nierenerkr., Phase 1/2, CHina].  
<https://www.clinicaltrials.gov/study/NCT05512988?intr=UC-MSCs&aggFilters=phase:1%200,status:rec&rank=4>. Updated July 10, 2023. Accessed July 31, 2024.
72. ClinicalTrials.gov. NCT04255147: Cellular Therapy for Extreme Preterm Infants at Risk of Developing Bronchopulmonary Dysplasia. [Phase 1, Canada].  
<https://www.clinicaltrials.gov/study/NCT04255147>. Updated July 10, 2023. Accessed July 31, 2024.
73. ClinicalTrials.gov. NCT05035862: Mechanisms of Interferon Gamma-primed Mesenchymal Stromal Cells (MSCs) for Moderate-to-severe Persistent Asthma. [Phase 1, USA].  
<https://www.clinicaltrials.gov/study/NCT05035862>. Updated July 10, 2023. Accessed July 31, 2024.
74. ClinicalTrials.gov. NCT04104412: The Safety/Efficacy Study of Human Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-LDP) for Lumbar Discogenic Pain. [Phase 1, China].  
<https://www.clinicaltrials.gov/study/NCT04104412>. Updated July 10, 2023. Accessed July 31, 2024.
75. ClinicalTrials.gov. NCT04744116: Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease. [Phase 1, USA]. <https://www.clinicaltrials.gov/study/NCT04744116>. Updated July 10, 2023. Accessed July 31, 2024.
76. ClinicalTrials.gov. NCT04873752: A Study to Investigate the Safety and Efficacy of UC-MSCs in Pediatric Patients With Cerebral Palsy.  
<https://clinicaltrials.gov/ct2/show/NCT04873752?recrs=abdf&cond=cerebral+palsy&intr=UC-MSCs&draw=2&rank=1>. Updated February 14, 2022.000Z. Accessed July 31, 2024.
77. ClinicalTrials.gov. NCT05490173: The Pilot Experimental Study of the Neuroprotective Effects of Exosomes in Extremely Low Birth Weight Infants.  
<https://clinicaltrials.gov/ct2/show/NCT05490173?term=cerebral+palsy&recrs=abdf&intr=UC-MSCs&draw=2&rank=3>. Accessed July 31, 2024.

78. ClinicalTrials.gov. NCT04093336: Effect of Mesenchymal Stem Cells(MSCs) Transplantation for Acute Cerebral Infarction Patients. [Phase 1/2, China].  
<https://www.clinicaltrials.gov/study/NCT04093336>. Updated July 10, 2023. Accessed July 31, 2024.
79. ClinicalTrials.gov. NCT05008588: Combination of Conditioned Medium and Umbilical Cord-Mesenchymal Stem Cells Therapy for Acute Stroke Infarct. [Phase 1/2, Indonesien].  
<https://www.clinicaltrials.gov/study/NCT05008588?intr=UC-MSCs&aggFilters=phase:1%200,status:rec&rank=7>. Updated July 10, 2023. Accessed August 3, 2023.
80. ClinicalTrials.gov. NCT03383081: A Clinical Research on the Safety/Efficacy of Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-OA) Therapy for Patients With Osteoarthritis.  
<https://clinicaltrials.gov/ct2/show/NCT03383081>. Accessed July 31, 2024.
81. ClinicalTrials.gov. NCT04314661: Comparative Effectiveness of Arthroscopy and Non-Arthroscopy Using Mesenchymal Stem Cell Therapy (MSCs) and Conditioned Medium for Osteoarthritis (OA).  
<https://clinicaltrials.gov/ct2/show/NCT04314661?recrs=abdf&cond=Osteo+Arthritis&intr=UC-MSC+NOT+adipose&draw=2&rank=4>. Accessed August 3, 2023.
82. ClinicalTrials.gov. NCT05043610: MSCs for Prevention of MI-induced HF (PREVENT-TAHA). [Herzerkrankungen].  
<https://clinicaltrials.gov/ct2/show/NCT05043610?recrs=abdf&cond=heart&intr=UC-MSC&draw=2&rank=5>. Accessed July 31, 2024.
83. ClinicalTrials.gov. NCT03902067: UC-MSC Transplantation for Left Ventricular Dysfunction After AMI. <https://clinicaltrials.gov/ct2/show/NCT03902067?recrs=abdf&cond=heart&intr=UC-MSC&draw=2&rank=1>. Updated February 14, 2022.000Z. Accessed February 14, 2022.725Z.
84. ClinicalTrials.gov. NCT03562065: Treatment of Refractory Systemic Lupus Erythematosus by Allogeneic Mesenchymal Stem Cells Derived From the Umbilical Cord (MSC-SLE). [Status unknown]. <https://clinicaltrials.gov/ct2/show/NCT03562065>. Accessed July 31, 2024.
85. ClinicalTrials.gov. NCT04971980: Safety and Efficacy Study of Human Umbilical Cord-Derived Mesenchymal Stem Cells(BC-U001) for Rheumatoid Arthritis. [Status unknown].  
<https://www.clinicaltrials.gov/ct2/show/NCT04971980?recrs=abdf&cond=autoimmune&intr=UC-MSC&draw=2&rank=1>. Accessed July 31, 2024.
86. ClinicalTrials.gov. NCT03828344: Safety and Tolerability of a Single Intravenous Infusion of BX-U001 in Refractory Rheumatoid Arthritis.  
<https://www.clinicaltrials.gov/ct2/show/NCT03828344?recrs=abdf&cond=autoimmune&intr=UC-MSC&draw=2&rank=2>. Accessed July 31, 2024.
87. ClinicalTrials.gov. NCT05061030: Mesenchymal Stromal Cells to Treat Type 1 Diabetes in Children and Adolescents.  
<https://www.clinicaltrials.gov/ct2/show/NCT05061030?recrs=abdf&cond=autoimmune&intr=UC-MSC&draw=2&rank=3>. Accessed August 3, 2023.
88. ClinicalTrials.gov. NCT02997878: Selected Mesenchymal Stromal Cells to Reduce Inflammation in Patients With PSC and AIH (Merlin). [Phase 1/2, UK].  
<https://www.clinicaltrials.gov/study/NCT02997878>. Updated July 10, 2023. Accessed July 31, 2024.
89. ClinicalTrials.gov. NCT03917797. [Phase 2, Autoimmun, Chile].  
<https://www.clinicaltrials.gov/study/NCT03917797>. Updated July 10, 2023. Accessed July 31, 2024.
90. ClinicalTrials.gov. NCT05039411: Safety of Allogeneic Human Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) to Treat Perianal Fistulas Patients With Crohn's Disease. [Autoimmun; Phase 1; Malaysia]. <https://www.clinicaltrials.gov/study/NCT05039411>. Updated July 10, 2023. Accessed July 31, 2024.

91. ClinicalTrials.gov. NCT05279768: Stem Cells and Secretomes for Infertility Therapy in Polycystic Ovary Syndrome (PCOS) Patients With Insulin Resistance. [Autoimmun, Phase 1/2, Indonesien]. <https://www.clinicaltrials.gov/study/NCT05279768?intr=UC-MSCs&aggFilters=phase:1%200,status:rec&rank=2>. Updated July 10, 2023. Accessed August 3, 2023.
92. ClinicalTrials.gov. NCT05507697: Treatment With Human Umbilical Cord Mesenchymal Stem Cells for Refractory Diabetic Peripheral Neuropathy. [Phase 1/2, Autoimmun, China, Completed]. <https://www.clinicaltrials.gov/study/NCT05507697?intr=UC-MSCs&aggFilters=phase:2,status:rec&rank=10>. Updated July 10, 2023. Accessed July 31, 2024.
93. ClinicalTrials.gov. NCT05631717: The Study of Comparing the Efficacy and Safety of Human Umbilical Cord MSCs and Low-dose IL-2 in the Treatment of LN. <https://www.clinicaltrials.gov/study/NCT05631717?intr=UC-MSCs&aggFilters=phase:3,status:rec&rank=6>. Updated July 10, 2023. Accessed July 31, 2024.
94. ClinicalTrials.gov. NCT05286255: Mesenchymal Stromal Cells for COVID-19 and Viral Pneumonias. <https://clinicaltrials.gov/ct2/show/NCT05286255?recrs=abdf&cond=COVID-19&intr=UC-MSCs&draw=2&rank=2>. Accessed July 31, 2024.
95. ClinicalTrials.gov. NCT04896853: Treatment of Respiratory Complications Associated With COVID-19 Infection Using ProTrans<sup>®</sup>. <https://clinicaltrials.gov/ct2/show/NCT04896853?recrs=abdf&cond=COVID-19&intr=UC-MSCs&draw=2&rank=11>. Accessed August 3, 2022.
96. ClinicalTrials.gov. NCT05689008: UC-MSCs in the Treatment of Severe and Critical COVID-19 Patients With Refractory Hypoxia. <https://www.clinicaltrials.gov/study/NCT05689008?intr=UC-MSCs&aggFilters=phase:3,status:rec&rank=1>. Updated July 10, 2023. Accessed August 3, 2023.
97. ClinicalTrials.gov. NCT05682586: UC-MSCs in the Treatment of Severe and Critical COVID-19 Patients. [COVID-19, Phase 3, China]. <https://www.clinicaltrials.gov/study/NCT05682586>. Updated July 10, 2023. Accessed July 31, 2024.
98. ClinicalTrials.gov. NCT05699811: IFN $\alpha$  Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors. [Phase 1/2, Solide Tumore, China]. <https://www.clinicaltrials.gov/study/NCT05699811>. Updated July 10, 2023. Accessed July 31, 2024.
99. ClinicalTrials.gov. NCT05872659: Mesenchymal Stem Cells for Immune Non-responder Patients With HIV Infection. [Phase 1, China]. <https://www.clinicaltrials.gov/study/NCT05872659>. Updated July 10, 2023. Accessed July 31, 2024.
100. Sieburg HB, Cattarossi G, Muller-Sieburg CE. Lifespan differences in hematopoietic stem cells are due to imperfect repair and unstable mean-reversion. *PLoS Comput Biol*. 2013;9(4):e1003006. doi:10.1371/journal.pcbi.1003006.
101. Pillay J, den Braber I, Vrsekooop N, et al. In vivo labeling with 2H<sub>2</sub>O reveals a human neutrophil lifespan of 5.4 days. *Blood*. 2010;116(4):625-627. doi:10.1182/blood-2010-01-259028.
102. Park YM, Bochner BS. Eosinophil survival and apoptosis in health and disease. *Allergy Asthma Immunol Res*. 2010;2(2):87-101. doi:10.4168/aair.2010.2.2.87.
103. Siracusa MC, Comeau MR, Artis D. New insights into basophil biology: initiators, regulators, and effectors of type 2 inflammation. *Ann N Y Acad Sci*. 2011;1217:166-177. doi:10.1111/j.1749-6632.2010.05918.x.
104. Patel AA, Zhang Y, Fullerton JN, et al. The fate and lifespan of human monocyte subsets in steady state and systemic inflammation. *J Exp Med*. 2017;214(7):1913-1923. doi:10.1084/jem.20170355.
105. Kaestner L, Bogdanova A. Regulation of red cell life-span, erythropoiesis, senescence, and clearance. *Front Physiol*. 2014;5:269. doi:10.3389/fphys.2014.00269.



106. Franco RS. Measurement of red cell lifespan and aging. *Transfus Med Hemother*. 2012;39(5):302-307. doi:10.1159/000342232.
107. Seifert M, Küppers R. Human memory B cells. *Leukemia*. 2016;30(12):2283-2292. doi:10.1038/leu.2016.226.
108. Bönig H, Heiden M, Schüttrumpf J, Müller MM, Seifried E. Potenzial hämatopoetischer Stammzellen als Ausgangsmaterial für Arzneimittel für neuartige Therapien. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz*. 2011;54(7):791-796. doi:10.1007/s00103-011-1305-2.
109. Dalous J, Larghero J, Baud O. Transplantation of umbilical cord-derived mesenchymal stem cells as a novel strategy to protect the central nervous system: technical aspects, preclinical studies, and clinical perspectives. *Pediatr Res*. 2012;71(4 Pt 2):482-490. doi:10.1038/pr.2011.67.
110. Willing AE, Eve DJ, Sanberg PR. Umbilical cord blood transfusions for prevention of progressive brain injury and induction of neural recovery: an immunological perspective. *Regen Med*. 2007;2(4):457-464. doi:10.2217/17460751.2.4.457.
111. Saha A, Patel S, Xu L, et al. Human umbilical cord blood monocytes, but not adult blood monocytes, rescue brain cells from hypoxic-ischemic injury: Mechanistic and therapeutic implications. *PLoS ONE*. 2019;14(9):e0218906. doi:10.1371/journal.pone.0218906.
112. Davies JE, Walker JT, Keating A. Concise Review: Wharton's Jelly: The Rich, but Enigmatic, Source of Mesenchymal Stromal Cells. *Stem Cells Transl Med*. 2017;6(7):1620-1630. doi:10.1002/sctm.16-0492.
113. Arutyunyan I, Elchaninov A, Makarov A, Fatkhudinov T. Umbilical Cord as Prospective Source for Mesenchymal Stem Cell-Based Therapy. *Stem Cells Int*. 2016;2016:6901286. doi:10.1155/2016/6901286.
114. AWMF. Leitlinie der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (DGGG): Betreuung von gesunden reifen Neugeborenen in der Geburtsklinik. 2012. [https://www.awmf.org/uploads/tx\\_szleitlinien/024-005l\\_S2k\\_Betreuung\\_von\\_gesunden\\_reifen\\_Neugeborenen\\_2012-10-abgelaufen.pdf](https://www.awmf.org/uploads/tx_szleitlinien/024-005l_S2k_Betreuung_von_gesunden_reifen_Neugeborenen_2012-10-abgelaufen.pdf). Accessed January 8, 2020.
115. Frändberg S, Waldner B, Konar J, Rydberg L, Fasth A, Holgersson J. High quality cord blood banking is feasible with delayed clamping practices. The eight-year experience and current status of the national Swedish Cord Blood Bank. *Cell Tissue Bank*. 2016;17(3):439-448. doi:10.1007/s10561-016-9565-6.
116. Ciobotariu R, Scaradavou A, Ciobotariu I, et al. Impact of delayed umbilical cord clamping on public cord blood donations: can we help future patients and benefit infant donors? *Transfusion*. 2018;58(6):1427-1433. doi:10.1111/trf.14574.